Want to see NERV full AI Analyst Report?
Top Page
Minerva Neurosciences
(NASDAQ:NERV)
Select Model
Select Model
Rating:45Neutral
Price Target:
$3.00
▼(-44.75% Downside)
Action:Reiterated
Date:08/17/26
The score is primarily constrained by weak financial performance (no revenue, heavy operating losses, persistent cash burn, and negative equity), which materially elevates funding risk. Technical indicators are mixed with only mild near-term support, while valuation metrics provide limited support due to a negative P/E and no dividend. Corporate governance events are positive but secondary versus the core financial challenges.
Positive Factors
CNS therapeutic focus
A focused CNS strategy targets serious psychiatric and neurological conditions where unmet medical needs may support meaningful long-term opportunity. Advancing therapies in these areas gives the company a clearly defined development mission and potential commercial relevance if candidates achieve approval.
Negative Factors
No recurring revenue
The absence of reported revenue means the company has not yet established a recurring commercial revenue base to fund operations. Its financial outlook therefore remains dependent on successful clinical development, regulatory progress, and eventual commercialization rather than an existing operating franchise.
Read all positive and negative factors
Positive Factors
Negative Factors
CNS therapeutic focus
A focused CNS strategy targets serious psychiatric and neurological conditions where unmet medical needs may support meaningful long-term opportunity. Advancing therapies in these areas gives the company a clearly defined development mission and potential commercial relevance if candidates achieve approval.
Read all positive factors
Minerva Neurosciences (NERV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$151.84M
Dividend YieldN/A
Average Volume (3M)138.17K
Price to Earnings (P/E)―
Beta (1Y)1.28
Revenue GrowthN/A
EPS Growth-2012.66%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-28.37
Shares Outstanding47,747,560
10 Day Avg. Volume85,208
30 Day Avg. Volume138,169
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.24
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap2.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.10
Forecast
1Y Price Target
$8.50Price Target Upside56.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.54
Revenue Forecast (FY)N/A
Minerva Neurosciences Business Overview & Revenue Model
Company Description
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfol...
Minerva Neurosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -394.35M | -293.42M | 6.02M | -21.69M | -24.69M | -45.28M |
| Net Income | -394.35M | -293.42M | 1.44M | -30.01M | -32.11M | -49.91M |
Balance Sheet | ||||||
| Total Assets | 95.09M | 97.97M | 37.14M | 56.90M | 55.09M | 77.12M |
| Cash, Cash Equivalents and Short-Term Investments | 75.27M | 82.30M | 21.36M | 40.91M | 36.09M | 60.76M |
| Total Debt | 0.00 | 64.96M | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 296.65M | 238.72M | 62.84M | 85.36M | 75.11M | 69.15M |
| Stockholders Equity | -201.56M | -140.75M | -25.69M | -28.46M | -20.02M | 7.98M |
Cash Flow | ||||||
| Free Cash Flow | -18.78B | -13.51B | -19.55M | -14.78M | -24.66M | -24.60M |
| Operating Cash Flow | -18.78B | -13.51B | -19.55M | -14.78M | -24.65M | -24.60M |
| Investing Cash Flow | -50.13B | 0.00 | 0.00 | 0.00 | -16.33K | 0.00 |
| Financing Cash Flow | 11.32B | 74.45B | 0.00 | 19.60M | -5.00 | 60.00M |
Minerva Neurosciences Technical Analysis
Negative
5.43
Price Trends
4.07
Negative
4.35
Negative
5.04
Negative
Market Momentum
-0.26
Negative
33.29
Neutral
19.40
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NERV, the sentiment is Negative. The current price of 5.43 is above the 20-day moving average (MA) of 3.46, above the 50-day MA of 4.07, and above the 200-day MA of 5.04, indicating a bearish trend. The MACD of -0.26 indicates Negative momentum. The RSI at 33.29 is Neutral, neither overbought nor oversold. The STOCH value of 19.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NERV.
Minerva Neurosciences Risk Analysis
Minerva Neurosciences disclosed 75 risk factors in its most recent earnings report. Minerva Neurosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Minerva Neurosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $5.33M | -1.33 | -109.26% | ― | -100.00% | 49.19% | |
45 Neutral | $151.84M | -0.11 | 250.02% | ― | ― | -2012.66% | |
45 Neutral | $11.70M | -1.27 | -47.22% | ― | -91.94% | 55.29% | |
42 Neutral | $10.00M | -1.35 | -70.81% | ― | ― | 56.99% |
* Healthcare Sector Average
NERV
Minerva Neurosciences
3.18
0.65
25.69%
BLRX
Bioline RX Ltd Sponsored ADR
2.22
-1.63
-42.44%
PULM
Pulmatrix
1.46
-3.44
-70.20%
CMMB
Chemomab Therapeutics
1.38
-1.98
-58.93%
ASBP
Aspire Biopharma Holdings
8.30
-372.22
-97.82%
Minerva Neurosciences Corporate Events
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Minerva Neurosciences Elevates Aliquo to Accounting Leadership
Positive
Aug 12, 2026
On August 10, 2026, Minerva Neurosciences’ board appointed Vice President and Controller Anthony Aliquo as Chief Accounting Officer and principal accounting officer, marking a promotion that reflects his progressive roles within the company ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.